The macro regime improved to a constructive Neutral reading on October 26: fell 5.45% to 18.39 from 19.45 and now sits 1.61 points below the 20 risk-off threshold, the 10-year Treasury yield held essentially flat at 4.986% versus 4.988%, and every major U.S. index closed higher, with the S&P 500 +0.70%, the Nasdaq +0.82%, the Dow +0.28% and the Russell 2000 +0.38%. JNJ participated, rising 0.94% to $266.30 from $263.81 on 5.77M shares (0.74x the 20-day average of 7.82M and 0.77x the 60-day average of 7.47M), but the intraday tape told a two-sided story: the session high of $272.36 cleared the October 22 high of $269.67 and the September 17 high of $270.87, then sellers reasserted and the stock closed $6.06 (2.28%) below that high, still short of the $273.73-$275.23 September supply cluster. The breakout from October 22 remains structurally intact: price sits 2.92% above the 20-day of $258.74, 1.97% above the 50-day of $261.15 and 10.11% above a rising 200-day of $241.86, with the 50-day 7.98% above the 200-day so the golden-cross configuration is unbroken. Momentum is the strongest part of the setup: the histogram printed +1.3835, the fourth consecutive positive reading and the highest of the entire 30-session window, while (14) at 55.38 sits in bullish territory with 15 points of headroom to overbought. Volume quality is the weakest part: recovered to 109.64M from 103.87M and is now marginally above the October 22 surge level, but it remains 30.1% below the September 17 peak of 156.84M, and the October 26 advance came on below-average volume, so the accumulation repair is real but incomplete. Fundamentals are unchanged in direction: 5.9% revenue growth still sits against -0.96% trailing earnings growth, the September-quarter adjusted of $2.59 beat by 2.69% but is roughly 7.5% below the $2.80 reported a year earlier, and the revision table remains one-sided, with zero upward revisions in any of the 0-quarter, +1-quarter, 0-year or +1-year buckets over either the last 7 or the last 30 days. The forward estimate line is the single most important number in the file: the +1-year consensus of $11.6175 is 5.29% below its level seven days ago and 9.43% below ninety days ago, and although those figures are unchanged from the prior reading (so the pace of cuts has stopped accelerating), stabilization is not the same as recovery. At $266.30 the stock trades at 22.92x forward earnings, 23.95x the current-year consensus of $11.11963, 40.41x trailing GAAP, 19.20x on a $662.50B enterprise value and 6.45x sales, with a 2.94 , a 2.89% free-cash-flow yield and a 2.03% dividend yield roughly 296 basis points below the 4.986% risk-free rate; upside to the $279.41 mean target is only 4.92%. News flow is stale but constructive, with the last supplied items dated September 27-28 and covering Tremfya's positive Phase 4 STAR result, Caplyta's Phase 3 bipolar-mania win (approximately 46% clinical response versus 21% on placebo), 16.9% operational oncology growth to $14.4B in H1 2026 and FY26 guidance of roughly $101.1B in sales with adjusted of $11.58-$11.68 depending on the operational versus reported basis cited. The next earnings report is January 26, 2027, 91 days away, so there is no company binary inside the near-term window and the position carries de facto macro event risk in its place. The single risk that matters is a daily close back below $259.04, which would negate the October 22 breakout and return the stock to the pre-breakout range; conversely a sustained close above $275.23 on volume above 7.82M, ideally with the first upward revision to the +1-year estimate, is what would justify upgrading the overall rating from HOLD to BUY.
Decision
Live price
$266.30
Recommendation score
57%
57%
Confidence
62%
62%
Outlook by horizon
1M
BUY
Near
6M
HOLD
Mid
1Y
HOLD
Long
Primary catalyst
The October 26 tape is the single most market-moving item available, because the supplied news flow is entirely stale (last item September 28) and there is no company event for 91 days. fell 5.45% to 18.39, the 10-year Treasury yield held at 4.986%, all major indices rose, and JNJ pushed to $272.36 intraday, clearing the October 22 high of $269.67 and the September 17 high of $270.87 before closing at $266.30. That session defines the near-term question precisely: the stock can reach the September supply shelf when volatility falls, but it cannot yet hold it, so the breakout remains a volatility-and-yield trade rather than an estimate-driven re-rating.
Maintain a full normal-weight core position for existing holders and do not add above $267 while price is directly beneath the $273-$275 September supply shelf. With at 18.39, only 4.92% upside to the mean target, zero upward estimate revisions in any bucket and the October 26 advance on 0.74x average volume, new capital should be limited to half a normal tranche inside the $259-$266 retest zone, with the remainder released only on a sustained close above $275.23 on volume exceeding 7.82M or on the first upward revision to the +1-year estimate. Size for roughly 2.4% daily volatility ( $6.51) and a 91-day wait for the next fundamental datapoint.
Thesis Snapshot
Why It Works
The bull case is that the October 22 breakout not only survived its retest but extended, and the momentum behind it is the strongest in the entire window: JNJ closed at $266.30 on October 26 after trading to $272.36, clearing both the October 22 high of $269.67 and the September 17 high of $270.87, with the higher-low sequence from $245.17 to $251.50 to $259.04 to $262.40 to $265.04 fully intact. The long-term structure never broke: price is 10.11% above a rising 200-day of $241.86, the 50-day sits 7.98% above the 200-day, and the 20-day at $258.74 is now 2.92% below the close. Momentum confirms the turn: the histogram expanded to +1.3835 from +1.1171, the fourth consecutive positive reading and the highest in the 30-session window, with the line itself at -0.5021 and closing in on a positive crossover, while (14) at 55.38 leaves roughly 15 points before overbought. at 109.64M has retaken the October 22 surge level. The macro tailwind improved: fell 5.45% to 18.39 and the 10-year held at 4.986%, and JNJ outperformed the S&P 500's 0.70% gain. Fundamentally the franchise is intact: 67.77% gross margin, 25.74% operating margin, 20.02% , 5.9% revenue growth achieved while absorbing a 55.5% Stelara collapse, Tremfya up 72.5% to roughly $2.0B with positive Phase 4 STAR data, oncology up 16.9% operationally to $14.4B, a $101.1B FY26 sales guidance midpoint, six beats in seven supplied quarters averaging +2.44%, net debt of only 4.28% of market cap, $18.50B of free cash flow and a 2.03% dividend. On the prior published plan the $259-$264 entry zone was tagged on October 23 ($262.40 low, $263.81 close), the $251.00 stop has not been approached since (lowest print $265.04 on October 26), and the $279-$287 exit band has not been reached, so the position is working with defined risk and roughly 4.9% remaining to consensus.
What Breaks It
The strongest argument against owning JNJ at $266.30 is that the stock has now fully round-tripped a post-earnings decline and then some, without any recovery in the earnings estimates that caused it: at $263.73 on October 12 the market was discounting a $12.27 out-year number; at $266.30 on October 26 it is discounting $11.6175, 5.3% lower, so the forward multiple has expanded to 22.92x against a shrinking denominator. The rally is a volatility-and-yield event, not a company event: the triggers were a 19.3-basis-point collapse in the 10-year yield on October 22 and a 5.45% drop in to 18.39 on October 26, and the October 26 session itself ended badly, with the stock $6.06 (2.28%) below its $272.36 high and still capped beneath the $273.73-$275.23 September ceiling. Every fundamental marker points the wrong way: TTM earnings growth is -0.96%, the September-quarter adjusted of $2.59 is roughly 7.5% below the $2.80 reported a year earlier, the +1-quarter estimate fell 4.35% in a week, the +1-year estimate is down 9.43% over ninety days, and there have been zero upward revisions in any bucket over either 7 or 30 days. The valuation cushion is thin: 22.92x forward, 23.95x current-year, 40.41x trailing GAAP, 2.94, a 2.89% free-cash-flow yield and a 2.03% dividend yield roughly 296 basis points under the risk-free rate, with only 4.92% upside to the $279.41 mean target and the $190 low target implying roughly 28.7% downside. The current-year consensus of $11.11963 sits roughly 4.0-4.8% below management's own $11.58-$11.68 guidance figures, so the market still is not underwriting the company's framework. And the tape is thinner than the price implies: at 109.64M remains 30.1% below the September 17 peak of 156.84M, the October 26 advance came on 0.74x average volume, and short interest of just 1.02% of float with 3.46 days to cover means there is no squeeze fuel behind the move. The clean short thesis is that a volatility-driven defensive squeeze has handed investors a gift exit at roughly 5% below consensus against an earnings base that is still falling, with 91 days of unhedged macro risk and no company catalyst in between.
A daily close back below $259.04, the October 22 low and essentially the 20-day at $258.74, would negate the breakout and re-establish the October 15 $262.45 lower high, shifting the near-term rating back toward HOLD-with-bearish-bias; a close below $251.50 would break the higher-low sequence, invalidate the base entirely and warrant moving the near-term rating to SELL with $245.17 and the $241.86 200-day as targets. Conversely, a sustained hold above $275.23 (the September 24 high) on volume above the 7.82M 20-day average, ideally accompanied by the first upward revision to the +1-year estimate, would justify upgrading the overall rating to BUY rather than merely the one-month view.
The advance is macro-dependent and already showed supply at the target: it was driven by a 19.3-basis-point drop in the 10-year Treasury yield on October 22 and a 5.45% decline to 18.39 on October 26, while the October 26 session closed $6.06 (2.28%) below its $272.36 high, showing that a yield backup or move back through 20 would strip the support without any change in company fundamentals.
Valuation remains demanding: forward is 22.92x, current-year is 23.95x, trailing GAAP is 40.41x, is 2.94, TTM earnings growth is -0.96%, the free-cash-flow yield is 2.89% against a 4.986% risk-free rate, upside to the $279.41 mean target is only 4.92% and the $190 low target implies roughly 28.7% downside.
Forward estimate erosion has persisted with no interruption: the +1-year estimate of $11.6175 is 9.43% below its ninety-day-ago level and 5.29% below seven days ago, the +1-quarter estimate dropped 4.35% in a week to $2.67986, and the 0-quarter, 0-year and +1-year buckets each logged two downward revisions over 30 days against zero upward revisions in any bucket.
The consensus-versus-guidance gap remains unexplained: the current-year estimate of $11.11963 is roughly 4.8% below the $11.68 adjusted midpoint cited in one supplied article and about 4.0% below the $11.58 adjusted operational figure cited in another, suggesting analysts either expect a guidance cut or are modeling items the operational guidance excludes, and the bundle does not reconcile the two figures.
Volume quality is deteriorating at the margin: the October 26 advance came on 5.77M shares, 0.74x the 20-day average of 7.82M, while at 109.64M remains 30.1% below the September 17 peak of 156.84M, so price is making higher highs on weaker participation.
The macro backdrop is unstable beneath a still-elevated volatility surface: 20-day realized volatility of 31.84% against a 0.206 beta means the stock can move 2-3% on flows alone ( $6.51 = 2.44% of price) despite its defensive classification, and the 2.03% dividend yield remains roughly 296 basis points below the 4.986% 10-year Treasury.
Product replacement may not keep pace with patent erosion: Stelara fell 55.5% to $740M, MedTech grew only 3.6% operationally and missed consensus at $8.93B versus $8.97B, and Tremfya, while growing 72.5% to about $2.0B, must still close a multi-billion-dollar gap that analysts are now modeling as slower than they did a quarter ago.
Data coverage has gaps that limit confidence: Bollinger Band statistics are null for every session, insider transaction_type and date fields are blank or ordinal placeholders, the number of analysts field is null, and there is no peer or historical multiple series in the bundle, so relative valuation, squeeze-versus-expansion volatility reads and insider direction all have to be inferred rather than measured.
Watch Next
Next earnings: Jan 26, 2027
The October 26 tape is the single most market-moving item available, because the supplied news flow is entirely stale (last item September 28) and there is no company event for 91 days. fell 5.45% to 18.39, the 10-year Treasury yield held at 4.986%, all major indices rose, and JNJ pushed to $272.36 intraday, clearing the October 22 high of $269.67 and the September 17 high of $270.87 before closing at $266.30. That session defines the near-term question precisely: the stock can reach the September supply shelf when volatility falls, but it cannot yet hold it, so the breakout remains a volatility-and-yield trade rather than an estimate-driven re-rating.
Signal Dashboard
Decision inputs
6 signals
Fundamental
4.9%
Upside to analyst mean target
At the October 26 close of $266.30 JNJ trades at 22.92x the $11.6175 forward consensus, 23.95x the current-year consensus of $11.11963, 40.41x trailing GAAP earnings, 19.20x on a $662.50B enterprise value against a $641.07B market cap (EV/market cap 1.03), 6.45x sales and 7.86x book value, with a supplied of 2.94 and TTM earnings growth of -0.96%. The multiple is unchanged in substance from the prior session because price and the estimate denominator moved together, which is precisely the problem: the stock is not getting cheaper as it rises. Revenue growth of 5.9% does not on its own justify 6.45x sales, and 22.92x forward is defensible only if the out-year estimate stops falling. There is no yield cushion either: the 2.03% dividend yield sits roughly 296 basis points below the 4.986% 10-year Treasury, so JNJ is not functioning as a bond substitute at current rates. The reported $18.50B of trailing free cash flow against a $641.07B market cap produces a 2.89% FCF yield, which is below the risk-free rate and therefore offers no absolute valuation support. Upside to the $279.41 mean target is 4.92%, to the $280.50 median 5.33%, and to the $320 high 20.17%, versus a $190 low target implying roughly 28.7% downside; the $130 high-to-low spread equals 48.8% of the share price and signals genuine disagreement about the speed of the Stelara replacement. The bundle supplies no peer or historical multiple series, so a defensible relative discount or premium cannot be established; on absolute yield, growth and evidence the stock screens expensive rather than fairly valued.
Technical
Bullish
Trend quality
The uptrend is intact and has extended its higher-high sequence, but the October 26 session ended with a rejection candle rather than a clean breakout. At $266.30 the price sits 2.92% above the 20-day of $258.74, 1.97% above the 50-day of $261.15 and 10.11% above a steadily rising 200-day of $241.86. The 50-day remains 7.98% above the 200-day , so the golden-cross configuration in place through 2026 shows no death-cross proximity. The intraday high of $272.36 cleared both the October 22 high of $269.67 and the September 17 high of $270.87, confirming the stock can attack the September supply shelf, but it stalled below the $273.73 (September 21), $273.78 (September 28) and $275.23 (September 24) cluster and closed $6.06 off the high. The higher-low structure remains valid: $245.17 (October 13) to $251.50 (October 19) to $259.04 (October 22) to $262.40 (October 23) to $265.04 (October 26). The characterization is an intact uptrend pressing into overhead supply, with the October 26 close of $266.30 still below the $267.61 October 22 closing high.
Earnings
91d
Decelerating
The September 2026 quarter reported adjusted of $2.59 versus a $2.52225 estimate, a 2.69% beat and the sixth beat in seven supplied quarters, but the actual sits below the $2.80 reported in the September 2025 quarter, roughly -7.5% year over year, extending a deceleration visible in the sequence $2.77 (Q1 2025), $2.77 (Q2 2025), $2.80 (Q3 2025), $2.46 (Q4 2025), $2.70 (Q1 2026), $2.90 (Q2 2026), $2.59 (Q3 2026); shares fell 5.73% on October 13 on 16.65M shares (about 2.1x the 20-day average) and have since recovered to $266.30, above the pre-report $263.73 close. Only seven quarters are supplied rather than eight, and the bundle still contains no post-report article explaining the initial 5.73% decline, so whether it reflected guidance, MedTech softness, Stelara commentary or the quality of the beat cannot be confirmed from supplied evidence. The guidance read is two-sided: the quarterly beat record supports an under-promise/over-deliver style, but the current-year consensus of $11.11963 sits roughly 4.0-4.8% below the $11.58-$11.68 adjusted guidance figures cited in supplied coverage, which means the market is still not fully underwriting management's own framework.
News
Mixed-Bullish
Headline tone
The October 26 tape is the single most market-moving item available, because the supplied news flow is entirely stale (last item September 28) and there is no company event for 91 days. fell 5.45% to 18.39, the 10-year Treasury yield held at 4.986%, all major indices rose, and JNJ pushed to $272.36 intraday, clearing the October 22 high of $269.67 and the September 17 high of $270.87 before closing at $266.30. That session defines the near-term question precisely: the stock can reach the September supply shelf when volatility falls, but it cannot yet hold it, so the breakout remains a volatility-and-yield trade rather than an estimate-driven re-rating.
Macro
Neutral
4.99% 10Y / 18.4 VIX
at 18.39 sits comfortably inside the neutral band and is falling, which supports a low-beta dividend payer, but the 10-year Treasury yield at 4.986% still exceeds JNJ's 2.03% dividend yield by roughly 296 basis points, so any renewed backup in yields would compress this stock's multiple even though its defensive business mix provides relative downside support.
Stability
Defensive Compounder
Core Anchor
Johnson & Johnson earns the defensive-compounder label on franchise economics rather than on tape behavior: a 67.77% gross margin, 25.74% operating margin, 34.73% margin, 20.02% , 8.46% , a 0.206 beta and $18.50B of free cash flow against a 2.03% dividend mean neither solvency nor the distribution is at risk even if the Stelara replacement cycle runs longer than consensus expects. The Core Anchor role fits because the position's job is long-duration total return plus income, not tactical alpha, and its 76.83% institutional ownership with only 1.02% of float sold short keeps flow-driven volatility contained relative to the broad market. Drawdown risk stays Medium rather than Low because 20-day realized volatility is 31.84% against that 0.206 beta and (14) of $6.51 equals 2.44% of price, so 2-3% daily moves happen on no company-specific news, and the stock is still 5.25% below its $281.07 52-week high while the +1-year estimate sits 9.43% below its level ninety days ago. Thesis durability is High because the risk here is multiple compression and a temporarily shrinking earnings base, not franchise erosion, funding stress or balance-sheet impairment.
Analyst Spread
Mean Target
$279.41
High / Low
$190 / $320
Median Target
$280.50
Consensus range
$190 - $320
— analysts
Mean
$190$279$320
Consensus
The mean target of $279.41 and median of $280.50 imply only 4.92% and 5.33% upside from $266.30, while the $190 low target implies about 28.7% downside and the $320 high about 20.2% upside, a $130 spread equal to roughly 48.8% of the current share price that signals genuine disagreement about how fast Tremfya and oncology can replace Stelara. The recommendation distribution is 5 Strong Buy, 11 Buy, 6 Hold and 1 Sell across 23 ratings, identical across the 0m, -1m, -2m and -3m periods, meaning ratings have been frozen for at least three months while price targets were cut and then partially restored. That divergence, static ratings and moving targets, with targets now converging on the share price rather than leading it, is itself the message: sell-side consensus offers limited incremental upside and cannot be treated as a catalyst. The explicit analyst count is null in this bundle, so coverage breadth is inferred from the 23 ratings, and the October 16 Wells Fargo raise to $287 remains the most constructive datapoint in the set.
Positioning Pulse
Insider Signal
Neutral
Net Bias
Balanced
Insider Own.
0.1%
Institutional Own.
76.8%
Interpretation
Because direction and transaction mechanics are unverifiable in this extract and the filing count is only four, the insider data carry no usable signal about management's near-term confidence and should not influence the recommendation in either direction.
Notable activity
The extract lists CEO Joaquin Duato at 126,369 shares with a reported value of approximately $12.64M, COO Kathryn Wengel at 32,762 shares and approximately $3.28M, CFO Joseph Wolk at 13,015 shares and approximately $2.00M, and Director Mark Weinberger at 1,000 shares and approximately $147,220. The transaction_type field is blank for every row and the date field contains only ordinal placeholders ('68' through '71'), so the extract cannot establish direction, open-market versus award activity, or 10b5-1 plan status; the CEO's 126,369-share entry is far more consistent with an equity award or option-related event than a discretionary open-market purchase of that size, and only four rows are present, so no net-balance assessment can be reproduced.
Market Context
Industry
Drug Manufacturers - General
Mixed-Bullish
Sentiment
24
Tracked names
5
Grouping
industry
Drug Manufacturers - General industry is currently Mixed-Bullish with an average recommendation score near 60. capital and conviction are improving across the group, and leadership is concentrated in LLY, ABBV, AMGN.
Rotation Drivers
Average recommendation deltas are trending higher across Drug Manufacturers - General industry, which suggests improving risk appetite inside the group.
2 names are rated bullish versus 0 bearish names, keeping the group tone mixed-bullish.
Leadership is concentrated in LLY, ABBV, AMGN, so those names are the cleanest read on group-level capital rotation.
The relevant sector context is diversified large-cap pharma with MedTech exposure, and the rotation turned modestly in its favor again on October 26 after fading on October 23. The evidence is constructive but not decisive: fell 5.45% to 18.39, the 10-year Treasury yield held flat at 4.986%, and JNJ gained 0.94% versus the S&P 500's 0.70%, but the advance came on only 0.74x average volume and was rejected at $272.36. This remains a rotation and discount-rate signal rather than a fundamentals upgrade, and a broad-market up day is weaker evidence of rotation than the October 22 session when JNJ rose 3.81% while the S&P 500 fell 1.21% and the Nasdaq fell 2.60%.
The 10-year Treasury yield stabilized at 4.986% and dropped 5.45% to 18.39 on October 26, the exact combination that allows a 2.03%-yielding defensive name to re-rate, and the stock responded by probing the $272-$275 September supply shelf for the first time since the October 13 earnings drawdown.
October 22 was a clean intra-session rotation: JNJ +3.81%, Dow +0.02%, Russell 2000 +0.11%, S&P 500 -1.21%, Nasdaq -2.60%, with up 14.09% to 19.03, capital visibly leaving high-multiple growth for low-beta defensives.
October 26 showed the reverse mechanic working in JNJ's favor: -5.45% to 18.39, 10-year flat at 4.986%, S&P 500 +0.70%, Nasdaq +0.82% and JNJ +0.94%, so falling volatility now lifts the name alongside the market rather than only during risk-off episodes.
JNJ's one-month return of -1.81% and year-to-date return of -0.34% still lag the drug-industry return of +13.2% year to date cited in supplied coverage, so relative-value room exists, but the stock is already 5.25% below its 52-week high and only 4.92% below consensus, so the easy gap has mostly closed.
Biologic Loss-of-Exclusivity Replacement Cycle
Score: -22
Mixed-Bearish
The defining JNJ-specific narrative remains whether the immunology and oncology portfolio can replace a multi-billion-dollar Stelara revenue stream that fell 55.5% to $740M in Q2 and produced roughly a 760-basis-point operational drag. Tremfya's 72.5% growth to about $2.0B and the positive Phase 4 STAR study in axial psoriatic arthritis are genuine offsets, and oncology grew 16.9% operationally to $14.4B in H1 2026, but the arithmetic is not yet won: the out-year estimate sits at $11.6175, down 9.43% over ninety days, with zero upward revisions in any bucket. The theme score stays modestly negative because the four-session price recovery to $266.30 occurred without any estimate recovery, leaving the stock discounting a lower earnings base at a higher price than before the September-quarter report.
Price has recovered to $266.30, above the $262.45 breakout level and above the pre-report $263.73 close, while the +1-year estimate has been cut 9.43% over ninety days, so the divergence between price and earnings power must resolve either through estimate stabilization or renewed multiple compression.
Stelara declined 55.5% to $740M while Tremfya grew 72.5% to roughly $2.0B, and MedTech contributed only 3.6% operational growth and missed consensus at $8.93B versus $8.97B, leaving a visible gap between revenue lost and revenue gained.
The +1-year estimate of $11.6175 is 9.43% below its $12.82646 level ninety days ago and 5.29% below its level seven days ago, with zero upward revisions in the 0-quarter, 0-year or +1-year buckets over the last 30 days, indicating sell-side models are still being reset lower on replacement assumptions.
Sell-side price targets are converging on the share price rather than leading it: at $266.30 the $279.41 mean target implies only 4.92% upside and the October 14 cuts to $280 (RBC), $272 (Leerink) and $275 (Wells Fargo) sit close to the market, evidence that the re-underwriting is largely complete rather than that upside remains undiscovered.
Key Stats
23 metrics total
Market Cap
$641.07B
P/E (TTM)
40.4
Forward P/E
22.9
Revenue Growth
5.9%
ROE
20.0%
Beta
0.21
Full Metric Set
17 additional stats
Valuation Stack
Multiples and cash-flow framing.
Price / Sales
6.5
Price / Book
7.9
EV / EBITDA
19.2
Quality & Balance Sheet
Margins, leverage, and liquidity.
Gross Margin
67.8%
Operating Margin
25.7%
Debt / Equity
54.8
Current Ratio
1.02x
Quick Ratio
0.65x
Positioning & Range
Short interest and 52-week location.
Short % Float
1.0%
Short Ratio
3.46x
52W High
$281.07
52W Low
$184.66
From 52W High
-5.3%
From 52W Low
44.2%
Company Classification
Sector and industry context.
Sector
Healthcare
Industry
Drug Manufacturers - General
Additional Signals
Free Cash Flow
$18501875712.00
Detailed Analysis
Valuation
At the October 26 close of $266.30 JNJ trades at 22.92x the $11.6175 forward consensus, 23.95x the current-year consensus of $11.11963, 40.41x trailing GAAP earnings, 19.20x on a $662.50B enterprise value against a $641.07B market cap (EV/market cap 1.03), 6.45x sales and 7.86x book value, with a supplied of 2.94 and TTM earnings growth of -0.96%. The multiple is unchanged in substance from the prior session because price and the estimate denominator moved together, which is precisely the problem: the stock is not getting cheaper as it rises. Revenue growth of 5.9% does not on its own justify 6.45x sales, and 22.92x forward is defensible only if the out-year estimate stops falling. There is no yield cushion either: the 2.03% dividend yield sits roughly 296 basis points below the 4.986% 10-year Treasury, so JNJ is not functioning as a bond substitute at current rates. The reported $18.50B of trailing free cash flow against a $641.07B market cap produces a 2.89% FCF yield, which is below the risk-free rate and therefore offers no absolute valuation support. Upside to the $279.41 mean target is 4.92%, to the $280.50 median 5.33%, and to the $320 high 20.17%, versus a $190 low target implying roughly 28.7% downside; the $130 high-to-low spread equals 48.8% of the share price and signals genuine disagreement about the speed of the Stelara replacement. The bundle supplies no peer or historical multiple series, so a defensible relative discount or premium cannot be established; on absolute yield, growth and evidence the stock screens expensive rather than fairly valued.
Balance Sheet
Debt-to-equity of 54.77% equates to roughly 0.55x, a moderate leverage posture for a diversified healthcare company. Cash of $17.23B against $44.65B of total debt leaves net debt of $27.42B, only 4.28% of the $641.07B market cap, with a cash-to-debt ratio of 0.39. Cash generation is the offset: operating cash flow of $26.16B and free cash flow of $18.50B give an operating-cash-flow-to-debt ratio of 0.59, and that $18.50B covers the roughly $13.0B implied annual dividend (2.03% of market cap) about 1.42x. Returns are solid rather than spectacular at a 20.02% and 8.46% , with a current ratio of 1.02 and a quick ratio of 0.65 that look tight but are normal for a pharma carrying large receivables and inventory balances. Solvency is not a thesis risk at 4.28% net debt to market cap; the risk is that cash and debt capacity are being deployed into acquisitions and pipeline programs whose returns will not be visible for several years.
Growth
Revenue growth of 5.9% year over year coexists with earnings growth of -0.96%, and that gap remains the central tension. Under the surface, Tremfya grew 72.5% to roughly $2.0B in Q2 2026 and the Phase 4 STAR study in psoriatic arthritis with axial involvement met primary and secondary endpoints with MRI-confirmed reductions in joint inflammation, while H1 2026 oncology revenue rose 16.9% operationally to $14.4B, about 29% of company revenue, on Darzalex, Erleada, Carvykti, Tecvayli, Talvey and Rybrevant/Lazcluze. Against that, Stelara collapsed 55.5% to $740M on biosimilar entry for roughly a 760-basis-point operational drag, and MedTech grew only 3.6% operationally with Q2 sales of $8.93B below the $8.97B consensus on China electrophysiology inventory dynamics and softer U.S. Abiomed procedure trends. Management raised FY26 reported sales guidance to a $101.1B midpoint and adjusted to $11.68 (with a separate $11.58 adjusted operational figure cited in supplied coverage), but the current-year consensus of $11.11963 sits roughly 4.8% below $11.68 and about 4.0% below $11.58, so sell-side models remain positioned below management's own framework. The most damaging growth datapoint is the out-year line: $11.6175 versus $12.82646 ninety days ago means analysts now expect a materially slower 2027 replacement of Stelara than they did a quarter ago.
Business Quality
The margin structure remains elite for a diversified healthcare company: 67.77% gross margin, 25.74% operating margin and 34.73% margin, with a reported profit margin of 16.20% (the gap between and net margin reflects amortization, litigation and restructuring charges rather than operating deterioration). of 20.02% and of 8.46% confirm the franchise converts capital efficiently, though the 1.02 current ratio and 0.65 quick ratio show limited near-term liquidity buffer. Innovative Medicine plus MedTech diversification, regulatory barriers and global commercial scale continue to support a quality premium over a single-asset drug developer. Ownership is institutional (76.83%) with negligible insider ownership (0.05%) and short interest of just 1.02% of float at 3.46 days to cover, so there is no crowded short base to squeeze and no insider alignment to lean on. Business quality justifies a premium multiple in absolute terms; whether it justifies 22.92x forward against a 4.986% risk-free rate is a separate and still-unanswered question.
Capital Allocation
The 2.03% dividend yield with a supplied payout ratio of 80.12% looks stretched only because that ratio is computed on GAAP earnings of roughly $6.59 per share; annual dividends of about $5.41 per share against the $11.12 current-year adjusted consensus imply adjusted coverage closer to 2.1x, and against $18.50B of trailing free cash flow the roughly $13.0B dividend is covered about 1.42x. That is adequate rather than generous and leaves limited room for a large dividend increase without earnings recovery. The $14.6B Intra-Cellular Therapies acquisition adds a neuroscience growth option whose Caplyta Phase 3 bipolar-mania result (approximately 46% clinical response versus 21% on placebo, onset as early as day three, on a once-daily 42mg dose) is encouraging but is not an approval and carries no disclosed regulatory timeline or sales contribution. The Nanobiotix partnership concentrates further clinical spend: JNJ is now global sponsor of the pivotal NANORAY-312 Phase 3 for JNJ-1900, covering nearly all remaining costs, with final data expected in the first half of 2027 after a May 2026 FDA-cleared protocol amendment that removed the interim analysis and moved to an earlier final analysis. Cash of $17.23B does not cover $44.65B of debt, but recurring free cash flow makes net debt of $27.42B manageable. The bundle provides no share-count trend, buyback authorization or dilution detail beyond 2.407B shares outstanding, so the per-share effect of repurchases and stock compensation cannot be quantified.
Estimate Revisions
Revisions remain negative across every horizon and did not participate in the four-session price advance. The +1-year estimate of $11.6175 is 5.29% below its $12.26671 level seven days ago, 4.29% below $12.138 thirty days ago, 5.61% below $12.3075 sixty days ago and 9.43% below $12.82646 ninety days ago. The +1-quarter estimate of $2.67986 fell 4.35% over seven days from $2.80177, is 3.43% below $2.775 thirty days ago and 8.46% below $2.92752 ninety days ago. The current-quarter estimate of $2.91505 slipped 0.55% in a week from $2.93127 and is 3.16% below $3.01013 ninety days ago. The current-year estimate of $11.11963 is the lone stabilizer, up 0.41% over seven days from $11.07451, up 0.42% over thirty days and up 0.61% over sixty days, but it remains 4.63% below $11.65944 ninety days ago. Revision counts confirm the skew: the 0-quarter, 0-year and +1-year buckets each recorded two downward revisions over the last 30 days and one over the last seven, the +1-quarter bucket one in each window, and there have been zero upward revisions in any bucket over either period. One nuance is worth flagging honestly: every figure in the revision table is identical to the prior published reading, so no new cuts have been recorded in the last three sessions, which means the erosion has paused rather than reversed. Post-earnings price-target action is mixed rather than uniformly negative: RBC cut to $280 from $290, Wells Fargo cut to $275 from $282 and Leerink cut to $272 from $276 on October 14, Morgan Stanley trimmed to $292 from $294 on October 15, and Wells Fargo then raised its target back to $287 from $275 on October 16, which at $266.30 now implies 7.8% upside. Formal ratings remain unchanged across the last 90 days with zero upgrades, zero downgrades and zero initiations.